OmniCar is developed to make generation 1 CarT treatments safer. This will not only improve the response rate for patients, but will also increase the available cohort size for the treatment. This is because CarT is not an appropriate treatment for very frail patients at the moment, due to the high probability of adverse events.
CHM have developed their drug, and the way the drug is administered, in a different way to normal CarT. They hope this will minimise adverse events. In fact they are so confident of how it works, that they are investigating transfering this tech to other cancer types. Because of this, I havent really ever thought about any real overlap between CHM and Omnicar, as the CHM drug does not seem to fit the Generation 1 CarT profile. CHM is more Gen 3.
CHM Price at posting:
31.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)